Document:

Exhibit 10.32

 

AMENDMENT #2

 

To Letter of Intent for Proposed CRADA #2166

 

“Pre-Clinical and Clinical Development of [*]”

 

The
purpose of this amendment is to change certain terms of the Letter of Intent
(LOI) for the proposed Cooperative Research and Development Agreement (CRADA)
entitled “Pre-Clinical and Clinical Development of [*].”
These changes are reflected below, and except for these changes, all other
provisions of the original CRADA LOI remain in full force and effect. Two
originals of this amendment are provided for execution; one is to remain with
the National Cancer Institute (NCI) and the other copy is to remain with the
Collaborator.

 

1.               Upon final
signature, the term of this CRADA Letter of Intent is extended for six months
from May 23, 2008 to November 23, 2008.

 

2.               Drs. Jeffrey
Abrams and James Zwiebel are added as NCI Principal Investigators. The NCI
Principal Investigators are Dr. Jeffrey Abrams, Dr. Sherry Ansher, Dr. James
Zwiebel and Dr. Howard Streicher.

 

 

	
   

  	
  ACCEPTED
  AND AGREED TO:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  For
  the National Cancer Institute:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  /s/Anna
  D. Barker

  	
   

  	
  06/24/08

  
	
  Anna D. Barker, Ph.D.

  	
   

  	
  Date

  
	
  Deputy Director, NCI

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  For
  NewLink Genetics Corporation:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  /s/Nicholas
  Vahanian

  	
   

  	
  7/7/2008

  
	
   

  	
   

  	
  DateExhibit 10.33

 

AMENDMENT #3

 

To Letter of Intent for Proposed CRADA #2166

 

“Preclinical and Clinical Development of [*]”

 

The
purpose of this Amendment is to change certain terms of the Letter of Intent
(LOI) for the proposed Cooperative Research and Development Agreement (CRADA)
entitled “Preclinical and Clinical Development of [*].”
These changes are reflected below, and except for these changes, all other
provisions of the original CRADA LOI remain in full force and effect. Two
originals of this Amendment are provided for execution; one is to remain with
the National Cancer Institute (NCI) and the other original is to remain with
the Collaborator.

 

Upon
final signature, the term of the CRADA Letter of Intent is extended for six
months from November 23, 2008 to May 23, 2009.

 

 

	
   

  	
  ACCEPTED
  AND AGREED TO:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  For
  the National Cancer Institute:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  /s/Anna
  D. Barker

  	
   

  	
  03/16/09

  
	
  Anna D. Barker, Ph.D.

  	
   

  	
  Date

  
	
  Deputy Director, NCI

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  For
  NewLink Genetics Corporation:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  /s/Nicholas
  Vahanian

  	
   

  	
  03/24/09

  
	
  Name:
  Nicholas Vahanian

  	
   

  	
  Date

  
	
  Title:
  COOExhibit 10.34

 

AMENDMENT #4

 

To Letter of Intent for Proposed CRADA #2166

 

“Preclinical and Clinical Development of [*]”

 

The
purpose of this Amendment is to change certain terms of the Letter of Intent
(LOI) for the proposed Cooperative Research and Development Agreement (CRADA)
entitled “Preclinical and Clinical Development of [*].”
These changes are reflected below, and except for these changes, all other
provisions of the original CRADA LOI remain in full force and effect. Two
originals of this Amendment are provided for execution; one is to remain with
the National Cancer Institute (NCI) and the other original is to remain with
the Collaborator.

 

Upon
final signature, the term of the CRADA Letter of Intent is extended for six
months from May 23, 2009 to November 23, 2009.

 

 

	
   

  	
  ACCEPTED
  AND AGREED TO:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  For
  the National Cancer Institute:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  /s/Anna
  D. Barker

  	
   

  	
  10/16/09

  
	
  Anna D. Barker, Ph.D.

  	
   

  	
  Date

  
	
  Deputy Director, NCI

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  For
  NewLink Genetics Corporation:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  /s/Nicholas
  Vahanian

  	
   

  	
  10/28/09

  
	
  Nicholas
  Vahanian

  	
   

  	
  Date

  
	
  Chief
  Operating OfficerExhibit 10.35

 

AMENDMENT #5

 

To Letter of Intent for Proposed CRADA #2166

 

“Preclinical and Clinical Development of [*]”

 

The
purpose of this Amendment is to change certain terms of the Letter of Intent
(LOI) for the proposed Cooperative Research and Development Agreement (CRADA)
entitled “Preclinical and Clinical Development of [*].”  These changes are reflected below, and except
for these changes, all other provisions of the original CRADA LOI remain in
full force and effect.  Two originals of
this Amendment are provided for execution; one is to remain with the National
Cancer Institute (NCI) and the other original is to remain with the
Collaborator.

 

Upon
final signature, the term of the CRADA Letter of Intent is extended for six
months from November 23, 2009 to May 23, 2010.

 

 

ACCEPTED
AND AGREED TO:

 

For the
National Cancer Institute:

 

	
  

  	
   

  	
  

  
	
  Anna
  D. Barker, Ph.D.

  	
   

  	
  Date

  
	
  Deputy
  Director, NCI

  	
   

  	
   

  

 

 

	
  For
  NewLink Genetics Corporation:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  

  	
   

  	
  

  
	
  Nicholas
  Vahanian, M.D.

  	
   

  	
  Date

  
	
  Chief
  Operating OfficerExhibit 10.36

 

AMENDMENT #6

 

To Letter of Intent for Proposed CRADA #2166

 

“Preclinical and Clinical Development of [*]”

 

The
purpose of this Amendment is to change certain terms of the Letter of Intent
(LOI) for the proposed Cooperative Research and Development Agreement (CRADA)
entitled “Preclinical and Clinical Development of [*].”  These changes are reflected below, and except
for these changes, all other provisions of the original CRADA LOI remain in
full force and effect.  Two originals of
this Amendment are provided for execution; one is to remain with the National
Cancer Institute (NCI) and the other original is to remain with the
Collaborator.

 

Upon
final signature, the term of the CRADA Letter of Intent is extended for six
months from May 23, 2010 to November 23, 2010.

 

 

	
  ACCEPTED
  AND AGREED TO:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  For
  the National Cancer Institute:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  

  	
   

  	
  

  
	
   

  	
   

  	
   

  
	
  Anna
  D. Barker, Ph.D.

  	
   

  	
  Date

  
	
  Deputy
  Director, NCI

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  For
  NewLink Genetics Corporation:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  

  	
   

  	
  

  
	
   

  	
   

  	
   

  
	
  Nicholas
  Vahanian, M.D.

  	
   

  	
  Date

  
	
  Chief
  Operating OfficerExhibit 10.37

 

THIS
LICENSE AGREEMENT is made and entered into as of this 13 day of September,
2005, by and between the MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC.,
a nonprofit Georgia corporation with offices located in the Medical College of
Georgia, 1462 Laney Walker Blvd, Room CA-2125, Augusta, Georgia 30912-4810
(hereinafter referred to as “MCGRI”) and NEWLINK GENETICS CORPORATION, a
Delaware corporation with corporate headquarters located at 2901 South Loop
Drive Suite 3900, Ames, Iowa 50010 (hereinafter referred to as “LICENSEE”).

 

WITNESSETH

 

WHEREAS,
the Medical College of Georgia Research Institute (MCGRI) is the assignee of
all right, title, and interest in inventions developed by employees of The
Medical College of Georgia (MCG) and is responsible for the protection and
commercial development of such inventions; and

 

WHEREAS,
David Munn, Andrew Mellor and Stephen Peiper, during the course of
his/her/their employment by the Medical College of Georgia (MCG), developed
certain inventions [*] as more
fully defined in Exhibit A; and

 

WHEREAS,
MCGRI wants to have the inventions further developed and made available in
commerce for use by the public; and

 

WHEREAS,
LICENSEE represents that it has the necessary expertise and resources to fully
develop and commercialize the inventions; and

 

WHEREAS,
LICENSEE wishes to obtain certain rights to pursue the development and
commercialization of the inventions; and

 

WHEREAS,
MCGRI wishes to grant LICENSEE such rights in accordance with the terms and
conditions of this Agreement.

 

NOW,
THEREFORE, for and in consideration of the mutual covenants and the premises
herein contained, the parties, intending to be legally bound, hereby agree as
follows.

 

ARTICLE 1.  DEFINITIONS

 

The
following terms as used herein shall have the following meaning:

 

1.1                                 “Affiliate”
shall mean, with respect to Licensee, a person, corporation or other entity
that, directly or indirectly, through one or more intermediaries, controls, is
controlled by or is under common control with Licensee. For the purposes of
this definition, “control” means the direct or indirect ownership of at least
twenty percent (20%) of the outstanding voting securities of the controlled
entity.

 

1.2                                 “Agreement” or “License
Agreement” shall mean this Agreement, including all Exhibits attached to this
Agreement.

 

1

 

1.3                                 “Field of Use”
means any and all medical applications, including without limitation,
prevention, diagnostics, and therapy, including action as an adjuvant.

 

1.4                                 “Improvement”
shall mean any invention, that is conceived or reduced to practice in the
laboratory of any Inventor (or of his/their collaborators), that relates to an
invention claimed in or covered by the Licensed Patents or which is a
modification of the inventions claimed in or covered by the Licensed Patents.

 

1.5                                 “Indemnitees”
shall mean MCGRI, MCGRI’s officers and directors, MCG, MCG’s employees, and the
Inventors, and their heirs, executors, administrators, and legal
representatives.

 

1.6                                 “Inventors”
shall mean David Munn, Andrew Mellor and/or Stephen Peiper, as applicable with
respect to each Licensed Patent.

 

1.7                                 “License
Agreement Year” shall mean the period from July 1 through June 30 of
each year during the term of this Agreement.

 

1.8                                 “Licensed
Patents” shall mean the patent applications and patents identified in EXHIBIT 
A hereof and any patent applications controlled by MCGRI that claim
Improvements, together with all divisionals, continuations,
continuations-in-part (to the extent directed to the subject matter
specifically described in such patent applications and patents), reissues, and
foreign counterparts of such applications or patents.

 

1.9                                 “Licensed
Product(s)” shall mean any process, service, or product, the manufacture, use,
or sale of which is covered by a Valid Claim or incorporates or uses any
Licensed Technology.

 

1.10                           “Licensed
Technology” shall mean all information and materials proprietary to MCGRI,
including designs, technical information, know how, knowledge, data, specifications,
test results and other information relating to the Licensed Patents and
disclosed by MCGRI to LICENSEE on the date of this Agreement or during the term
hereof on an exclusive, confidential basis and which is not available from
another source.

 

1.11                           “Licensed
Territory” means worldwide.

 

1.12                           “Net Selling
Price” of Licensed Products shall mean the gross revenues received by Licensee
or its Affiliate from a purchaser of a Licensed Product that is not a
Sublicensee of Licensee or its Affiliate (unless such Sublicensee is the end
user of such Licensed Product, in which case the amount received therefore
shall be deemed to be the amount that would be billed to a third party end user
in an arm’s-length transaction) including, if applicable, the value of all
properties and services received in consideration of a Sale of Licensed
Products, less the following items, as allocable to such Licensed Product (if
not previously deducted from the amount invoiced): (i) trade discounts,
credits or allowances; (ii) credits or allowances additionally granted
upon returns, rejections or recalls; (iii) freight, shipping and insurance
charges; (iv) taxes, duties or other governmental tariffs (other than
income taxes); and (v) government mandated rebates. Where a Sale is deemed
consummated by a gift, use, or other disposition

 

2

 

of
Licensed Products for other than a selling price stated in cash, the term “Net
Selling Price” shall mean the average gross selling price billed by LICENSEE in
consideration of the Sale of comparable Licensed Products during the three (3) month
period immediately preceding such Sale, without reduction of any kind;
provided, however, that transfers and use of Licensed Products in clinical
trials or for promotional or sampling purposes shall not be considered in
determining Net Selling Price.

 

If
the Licensed Products are Sold in combination with one or more other products
or services which are not Licensed Products, Net Selling Price for such
combination products will be calculated on a country-by-country basis by
multiplying actual net selling price of such combination products by the
fraction A/(A+B) where A is the average invoice price during the period of the
Licensed Product  when Sold separately, and B is
the average invoice price of any other product(s) or services in the
combination when Sold separately by Licensee. If the products or services in
the combination that are not Licensed Products are not Sold separately by
Licensee, Net Selling Price shall be calculated by multiplying actual net
selling price of such combination products by the fraction A/C  where A is the average invoice price of the Licensed
Product when Sold separately and C is the average invoice price of the
combination product. If neither the Licensed Product nor the combination
product is Sold separately by Licensee, then Net Selling Price for royalty
purposes hereunder for Sales of such combination product shall be determined by
multiplying the Net Selling Price (calculated in the manner described above) of
such combination product by a fraction, determined by mutual agreement of the
parties, that reflects the relative contribution in value that the Licensed
Product included in the combination product makes to the total value of such
combination product.

 

1.13                           “Sale” or “Sold”
shall mean the sale, transfer, exchange, or other disposition of Licensed
Products for value to a party other than LICENSEE or its Affiliate. Sales of
Licensed Products shall be deemed consummated upon the first to occur of: (a) receipt
of payment from the purchaser; or (b) if otherwise transferred, exchanged,
or disposed of for consideration other than cash whether by gift or otherwise
when such transfer, exchange, gift, or other disposition occurs.

 

1.14                           “MCG” shall
mean The Medical College of Georgia.

 

1.15                           “Sublicensee”
shall mean a third party to whom Licensee or its Affiliate has granted a
sublicense under the Licensed patents to make, use, sell, offer to sell or
import Licensed Products, beyond the mere right to purchase Licensed Product
from Licensee or its Affiliate.

 

1.16                           “Valid Claim”
shall mean a claim included among the issued and unexpired Licensed Patents so
long as such claim shall not have been irrevocably abandoned or held invalid in
an unappealable decision of a court or other authority of competent
jurisdiction.

 

3

 

ARTICLE 2.  GRANT OF LICENSE

 

2.1                                 License. MCGRI hereby
grants LICENSEE and its Affiliates an exclusive right and license under the
Licensed Patents and Licensed Technology to make, use, import, offer to sell
and sell Licensed Products for the Field of Use in the Licensed Territory
during the term of this Agreement.

 

2.2                                 Sublicensing. Licensee and
its Affiliates may sublicense to one or more third parties the rights granted
under this Agreement, subject to the prior approval of MCGRI, not to be
unreasonably withheld or delayed. If this Agreement is terminated for any
reason, any sublicenses granted shall remain in full force and effect and be
directly enforceable by MCGRI.

 

2.3                                 Retained
License.  MCGRI retains on behalf of
itself, MCG, the Inventors and any academic research collaborators, a
royalty-free right and license to make and use Licensed Products and to
practice Licensed Technology for research and educational purposes only.

 

2.4                                 No Implied
License. The license and right granted in this Agreement shall not be
construed to confer any rights upon LICENSEE by implication, estoppel, or
otherwise as to any technology not specifically identified in this Agreement as
Licensed Patents or Licensed Technology.

 

2.5                                 Government
Rights. The Licensed Patents, Licensed Technology, or portions thereof may
have been developed with financial or other assistance through grants or
contracts funded by the United States government. LICENSEE acknowledges that in
accordance with Public Law 96-517 and other statutes, regulations, and
Executive Orders as now exist or may be amended or enacted, the United States
government has certain rights in the Licensed Patents and Licensed Technology.
LICENSEE shall take all action necessary to enable MCGRI to satisfy its
obligations under any federal law relating to the Licensed Patents or Licensed
Technology.

 

2.6                                 Publications. MCGRI shall
have the right to publish any information included in the Licensed Patents
subject to the provisions of this § 2.5 and Article 9. MCGRI shall provide
to Licensee copies of any proposed presentation or publication or abstract
disclosing information included in the Licensed Patents prior to the submission
of such documents. Proposed publications and abstracts shall be supplied at
least thirty (30) days in advance of submission to a journal, editor, or third
party. Licensee may request reasonable changes and/or deletions be made in any
proposed publication in order to protect the Licensed Patents and Licensee’s
confidential information. MCGRI (or any of its personnel) will consider such
changes but retains the sole right to determine whether such changes or
deletions will be made; but MCGRI agrees that it will honor (and will cause its
personnel to honor) Licensee’s reasonable requests to remove any confidential
information of Licensee included in any such public disclosure. MCGRI agrees to
delay such proposed public disclosure for up to ninety (90) days and to use
commercially reasonable efforts to cooperate in the filing of a U.S. patent
application as provided in Article 7 covering such subject matter prior to
public disclosure.

 

4

 

ARTICLE 3.  DILIGENCE AND COMMERCIALIZATION

 

3.1                                 Licensee agrees
to invest [*] toward the further development of
Licensed Products in the field of cancer therapy within eighteen (18) months
after the execution date of the Agreement. If Licensee fails to make the required
investment, and does not remedy that failure within sixty (60) days after
written notice to Licensee, MCGRI, as its sole and exclusive remedy for such
failure, may convert Licensee’s right and license in the Field of Use for
oncology to non-exclusive.

 

3.2                                 Licensee agrees
to provide to MCGRI an annual report regarding Licensee’s (or its Affiliates’
or Sublicensees’) progress in other areas of Licensed Product development
(outside of cancer). MCGRI has the sole right to determine if non-cancer areas
are receiving due diligence in product development in accordance with standards
common to the industry, taking into account efficacy, the competitiveness of
alternative products in the marketplace, the patent and other proprietary
position of the Licensed Products, the likelihood of regulatory approval given
the regulatory structure involved, the profitability of the Licensed Product
and alternative products and all other relevant factors. If Licensee has not
met basic product development milestones, and does not remedy that failure
within sixty (60) days after written notice from MCGRI, Licensee’s right and
license in that area of the Field of Use (specifically, infectious disease or
diagnostics) will revert from exclusive to non-exclusive for that specific
application.

 

ARTICLE 4.  CONSIDERATION FOR LICENSE

 

4.1                                 License Fee. As partial
consideration for the license granted to LICENSEE under this Agreement,
LICENSEE shall pay MCGRI a license fee of [*]. The
license fee shall be paid in two equal installments of [*].
The first such installment shall be due within sixty (60) days of signing this
Agreement, and the second installment shall be due no later than six (6) months
after the first payment. Licensee will issue to MCGRI [*]
shares  of Licensee’s common stock (such
number of shares to be adjusted for any stock dividends, combinations, splits,
recapitalizations, and the like occurring after the effective date of the
Agreement), subject to execution and delivery by MCGRI of a stock subscription
agreement in the form of Exhibit B hereto. In regard to Improvement
technologies created after the signing of this Agreement, if LICENSEE elects to
include such technologies under this Agreement, there shall be a one-time
License Fee of [*] per technology, upon payment
of which the new technology is considered part of this Agreement.

 

4.2                                 Sublicensing
Fee. Licensee shall pay MCGRI [*] of any fees
or payments or remuneration paid to LICENSEE by a Sublicensee in relation to
this License and for rights to all or part of the Licensed Patents (other than  research funding, equity, loans or patent costs or fee

 

5

 

reimbursements).
Such percentage shall decrease [*] for each
year of the term of this Agreement in which Licensee expends at least [*] towards the development of Licensed Products, but not to
go below a floor of [*].

 

4.3                                 Royalties. As partial
consideration for the license granted to LICENSEE under this Agreement,
LICENSEE shall pay MCGRI the following royalties based on the Net Selling Price
of the applicable Licensed Products Sold by LICENSEE:

 

[*]

 

Notwithstanding
the foregoing, if Licensee is required to pay a royalty under a patent license
from any third party in order to sell a Licensed Product, then Licensee may reduce
the royalty otherwise payable to MCGRI on the Net Selling Price of such
Licensed Product by [*] of the
royalty amounts paid to such third party; provided, however, that in no event
will the royalty payable to MCGRI hereunder with respect to such Licensed
Product [*]. Royalties shall be payable on a
Licensed Product-by-Licensed Product and country-by-country basis from first
commercial sale of a Licensed Product in a country until the expiration of the
last to expire valid claim of the Licensed Patents claiming the manufacture,
use or sale of such Licensed Product in such country.

 

4.4                                 Minimum
Royalties. Prior to the first commercial sale of a Licensed
Product, Licensee shall pay to MCGRI an annual license fee equal to [*] per License Agreement Year, within sixty (60) days
following the end of each License Agreement Year. Following the first
commercial sale of a Licensed Product, within sixty (60) days after the end of
each License Agreement Year during the term of this Agreement thereafter, if
earned royalties for such License Agreement Year are less than [*], Licensee will pay to MCGRI a minimum annual royalty
equal to the difference (if any) between [*] and earned
royalties for such year. For any partial year for which a minimum annual
royalty is due hereunder, the amount of such minimum annual royalty shall be
pro-rated based on a 365-day year.

 

4.5                                 Reimbursement
for Patent Expenses. LICENSEE shall reimburse MCGRI for all reasonable,
documented out-of-pocket fees, costs, and expenses hereafter during the term of
this Agreement paid or incurred by MCGRI in filing, prosecuting, and
maintaining the Licensed Patents in the Licensed Territory. LICENSEE shall
provide such reimbursement for patent expenses within 30 days of receipt of the
itemized invoice.

 

6

 

4.6                                 Milestone
Payments to MCGRI.

 

4.6.1                        Within sixty
(60) days of the first achievement by any Licensed Product of the following
milestone events, Licensee shall pay (or issue) to MCGRI the indicated
consideration:

 

[*]

 

4.6.1.1               Initiation of [*]  [*]

 

4.6.1.2               Completion of [*]  [*]

 

For
clarity, each milestone payment above shall be due only once for a particular [*] regardless of the number of molecules directed towards
such [*] pursued in a particular disease
category.

 

4.6.1.3               Within sixty (60) days of
the achievement by each Licensed Product of the following milestone events,
Licensee shall pay to MCGRI the indicated amount:

 

4.6.1.4               [*]  [*]

 

4.6.1.5               [*]  [*]

 

For
clarity, each milestone payment indicated above shall be due each time the
milestone event is achieved by one or more Licensed Products.

 

ARTICLE 5.  REPORTS AND PAYMENTS

 

5.1                                 Within sixty
(60) days of September 30, December 31, March 31, and June 30
of each year during the term of this Agreement, up to and including September 30,
December 31, March 31 and June 30 following the termination or
expiration of this Agreement, LICENSEE shall render a written report to MCGRI
setting forth for the preceding calendar quarter, the following as may be
applicable under the royalty provisions hereof:

 

(a)                                  the Net Selling
Price of all Licensed Products Sold by LICENSEE, and its Affiliates and
Sublicensees under this Agreement; and

 

(b)                                 the amount of
royalty payable; and

 

(c)                                  any other
information reasonably necessary to show the basis on which such royalty has
been computed; and

 

(d)                                 the title of
the Licensed Patent(s), the Inventor(s), and the five digit MCG code(s) for
the Licensed Patent(s); and

 

(e)                                  in case no
payment is due for any calendar quarter hereunder, LICENSEE shall so report.

 

5.2                                 Each royalty
report shall be accompanied by the payment of all royalties due for the quarter
calendar year in question. Any minimum royalty payment due under Article 4
shall accompany the report for the quarter ending on June 30 of the
applicable License Agreement Year.

 

5.3                                 All royalties
shall be paid in United States funds collectible at one hundred percent (100%)
of face value in New York, New York, U.S.A. For purposes of computing the
royalty payment on 

 

7

 

Sales outside the United States, the royalty payment
hereunder shall first be determined in the foreign currency of the country in
which Licensed Products are Sold and then converted to United States dollars at
the spot rate published by the Wall Street Journal (U.S. edition) on the last
day of the quarter for which payment is due.

 

5.4                                 In high
inflation countries where LICENSEE uses accounting treatment under Statement of
Financial Accounting Standards No. 52, Paragraph 11, or the successor
equivalent Standard, LICENSEE may for each such country at the end of each
quarter convert each month’s Sales in that quarter to United States dollars by
assuming all Sales in that month occurred on the last day of the month,
computing the collection date for that month’s Sales to United States dollars
at the forecasted exchange rate for that computed collection date; differences
between the forecasted exchange rate and the actual exchange rate are to be
corrected in the first quarter in which known.

 

5.5                                 If Licensed
Products are Sold in a country in which conditions or legal restrictions exist
which prohibit remittance of United States dollars, LICENSEE shall have the
right and option to make the royalty payment for such country by depositing the
amount thereof in the currency of the country of Sale at LICENSEE’s election,
to MCGRI’s account in a bank designated by MCGRI in such country.

 

5.6                                 Interest.
Payments required under this Agreement shall, if overdue, bear interest until
payment at a per annum rate [*], on the due
date. The payment of such interest shall not foreclose MCGRI from exercising
any other rights it may have because any payment is late.

 

5.7                                 All payments
and reports due under this Agreement shall be made in person or via the United
States mail or private carrier to the following address:

 

Office
of Technology Transfer and Economic Development

Medical
College of Georgia

Attn:
Associate Vice President of Technology Transfer & Economic Development

CA-2125

Medical
College of Georgia

Augusta, Georgia 30912-9824

Facsimile: (706) 721-2917

 

8

 

5.8                                 All payments
should be made payable to:  The Medical College of Georgia Research Institute.

 

ARTICLE 6.  RECORDS

 

6.1                                 Records of
Sales. During the term of this Agreement and for a period of three (3) years
thereafter, LICENSEE shall keep at its principal place of business true and
accurate records of all Sales in accordance with general accepted accounting
principles in the respective country where such Sales occur and in such form
and manner so that all royalties owed to MCGRI may be readily and accurately
determined. LICENSEE shall furnish MCGRI copies of such records upon MCGRI’s
request, which shall not be made more often than once per License Agreement
Year.

 

6.2                                 Audit of
Records. MCGRI shall have the right, from time to time at reasonable times
during normal business hours through an independent certified public
accountant, to examine the records of LICENSEE in order to verify the calculation
of any royalties payable under this Agreement. Such examination and
verification shall not occur more than once each License Agreement Year and the
calendar year immediately following termination of this Agreement. Unless
otherwise agreed in writing by LICENSEE, the fees and expenses of performing
such examination and verification shall be borne by MCGRI. If such examination
reveals an underpayment by LICENSEE of more than five percent (5%) for any
quarter examined, LICENSEE shall pay MCGRI the amount of such underpayment plus
interest and shall reimburse MCGRI for all expenses of the accountant
performing the examination.

 

ARTICLE 7.  PATENT PROSECUTION

 

7.1                                 Prosecution and
Maintenance of Licensed Patents. The prosecution and
maintenance of the Licensed Patents shall be the primary responsibility of
MCGRI using counsel reasonably acceptable to LICENSEE. MCGRI shall keep
LICENSEE informed as to all developments with respect to Licensed Patents,
including by providing LICENSEE, in a timely manner prior to their due date,
with copies of all official documents and correspondence relating to the
prosecution, maintenance, and validity of the Licensed Patents. LICENSEE shall
be afforded reasonable opportunities to advise MCGRI and cooperate with MCGRI
in such prosecution and maintenance. LICENSEE shall advise MCGRI in which
countries LICENSEE desires patents be filed, and MCGRI will comply with any
such requests. MCGRI shall not unreasonably withhold consent to amend any
patent application to include any claims related to Licensed Patents and/or
Licensed Technology reasonably requested by LICENSEE to protect the Licensed
Products

 

9

 

contemplated
to be sold under this Agreement. If LICENSEE should fail to timely make
reimbursement for patent expenses incurred under this paragraph as required in Article 4.5
of this Agreement, MCGRI shall have no further obligation to prosecute or
maintain the Licensed Patents. MCGRI shall not finally abandon prosecution of
any patent application without first notifying LICENSEE sixty (60) days prior
to any bar date, of MCGRI’s intention and reason therefore, and providing
LICENSEE with reasonable opportunity to assume responsibility for prosecution,
maintenance and associated costs of such Licensed Patents.

 

LICENSEE,
upon ninety (90) days advance written notice to MCGRI, may advise MCGRI that it
no longer wishes to pay expenses for filing, prosecuting or maintaining one or
more Licensed Patents.  MCGRI may, at its
option, elect to pay such expenses or permit such Licensed Patents to become
abandoned or lapsed. If MCGRI elects to pay such expenses, such patents shall
not be subject to any license granted to LICENSEE hereunder.

 

7.2                                 Extension of
Licensed Patents. LICENSEE may request that MCGRI have the normal
term of any Licensed Patent extended or restored under a country’s procedure of
extending life for time lost in government regulatory approval processes, and
the expense of same shall be borne in accordance with the terms of Article 4.5.
LICENSEE shall assist MCGRI to take whatever action is necessary to obtain such
extension. In the case of such extension, royalties pursuant to Article 4
hereof shall be payable until the end of the extended life of the patent. In
the event that LICENSEE does not elect to extend Licensed Patent(s), MCGRI may,
at its own expense, effect the extension of such Licensed Patent(s). If MCGRI
elects to pay such expenses, such extended Licensed Patents shall not be
subject to any license granted to LICENSEE hereunder.

 

ARTICLE 8.  ABATEMENT OF INFRINGEMENT

 

8.1                                 Each party
shall promptly inform the other party of any suspected infringement of any
Licensed Patents. During the term of this Agreement, MCGRI and LICENSEE shall
have the right to institute an action for infringement of the Licensed Patents
against any such third party in accordance with the following and subject to
the rights of any third parties granted licenses to practice the Licensed
Patents by MCGRI:

 

(a)                                  If MCGRI and
LICENSEE agree to institute suit jointly, the suit shall be brought in both
their names [*] and any recovery or settlement
[*]. LICENSEE and MCGRI shall agree
upon the manner in which they shall exercise control over such action. MCGRI
may, if it so desires, also be represented by separate counsel of its own
selection. The fees for which counsel shall be paid by MCGRI;

 

10

 

(b)           In
the absence of agreement to institute a suit jointly, MCGRI may institute suit,
and, at its option, name LICENSEE as a plaintiff.  [*]of such
litigation and shall be entitled to [*]; and

 

(c)           In the absence of agreement to institute a suit jointly and
if MCGRI notifies LICENSEE that it has decided not to join in or institute a
suit, as provided in (a) or (b) above, LICENSEE may institute suit
and, at its option, name MCGRI as a plaintiff. 
[*]of such litigation, including
defending any counterclaims brought against MCGRI and paying any judgments
rendered against MCGRI, and shall be entitled to [*].

 

8.2           Should either MCGRI or LICENSEE commence a suit under the
provisions of this Article and thereafter elect to abandon such suit, the
abandoning party shall give timely notice to the other party who may, if it so
desires, continue prosecution of such suit, provided that [*] shall
be as agreed upon between MCGRI and LICENSEE.

 

ARTICLE 9.  CONFIDENTIALITY

 

9.1           LICENSEE shall not, without the express written consent of
MCGRI, for any reason or at any time either during or subsequent to the term of
this Agreement disclose any information contained in the Licensed Patents or
Licensed Technology or any other information pertaining to the Licensed Patents
and Licensed Technology (collectively referred to as “Proprietary Information”)
to third parties other than Affiliates and LICENSEE’s sublicensees. This
obligation of nondisclosure shall not extend to information:

 

(a)           which LICENSEE can demonstrate through documentation to
have been within LICENSEE’s legitimate possession prior to the time of
disclosure of such information to LICENSEE by MCGRI, MCG, or the Inventors;

 

(b)           which was in the public domain prior to disclosure by
MCGRI, MCG, or the Inventors, as evidenced by documents published prior to such
disclosure;

 

(c)           which, after disclosure by MCGRI, MCG, or the Inventors,
comes into the public domain through no fault of LICENSEE;

 

(d)           which is disclosed to LICENSEE by a third party having
legitimate possession of the information and the unrestricted right to make
such disclosure.

 

(e)           which is required by a valid court order or law, in which
case each party would notify the other.

 

9.2           All reports provided to MCGRI pursuant to this Agreement
shall be treated as confidential information of Licensee and shall not be
disclosed to any third party without the prior written consent of Licensee.
Except as expressly provided herein, each party agrees not to disclose any
terms of this Agreement to any third party without the consent of the other
party; provided, however, that disclosures may be made as required by
securities or other applicable laws, or to actual or prospective investors or
corporate partners, or to a party’s accountants, attorneys, and other
professional advisors.

 

11

 

9.3           Prior Agreements. The provisions of this Agreement
supersede and shall be substituted for any terms of any prior confidentiality
agreement between LICENSEE and MCGRI which are not consistent with this
Agreement.

 

ARTICLE 10.  MERCHANTABILITY AND EXCLUSION OF WARRANTIES

 

10.1         LICENSEE possesses the necessary expertise and skill in the
technical areas in which the Licensed Products and Licensed Technology are
involved to make, and has made, its own evaluation of the capabilities, safety,
utility, and commercial application of the Licensed Patents and Licensed
Technology. ACCORDINGLY, to the best of MCGRI’s knowledge based on reasonable
inquiry, MCGRI represents and warrants that: (i) the execution, delivery,
and performance of this Agreement have been duly authorized by all necessary
corporate action on the part of MCGRI; (ii) MCGRI is the sole and
exclusive owner of all right, title, and interest in the Licensed Patents; (iii) it
has the right to grant the rights and licenses granted herein; (iv) it has
not granted any third party any license, right or interest in any of the
Licensed Patents that is inconsistent with the rights granted to Licensee
herein and will not grant any third party such a right during the term of this
Agreement; and (v) there are no threatened or pending actions, suits,
investigations, claims, or proceedings in any way relating to the Licensed
Patents.

 

10.2         Except as expressly set forth in Section 10.1, MCGRI
MAKES NO REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE LICENSED
PATENTS OR LICENSED TECHNOLOGY AND EXPRESSLY DISCLAIMS ANY WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AND ANY OTHER IMPLIED
WARRANTIES WITH RESPECT TO THE CAPABILITIES, SAFETY, UTILITY, OR COMMERCIAL
APPLICATION OF LICENSED PATENTS OR LICENSED TECHNOLOGY.

 

ARTICLE 11.  DAMAGES, INDEMNIFICATION, AND INSURANCE

 

11.1         NO LIABILITY. MCGRI shall not be liable to LICENSEE
or LICENSEE’s customers for special, incidental, indirect, or consequential
damages resulting from defects in the design, testing, labeling, manufacture,
or other application of Licensed Products manufactured, tested, designed, or
Sold pursuant to this Agreement.

 

11.2         Indemnification. LICENSEE shall defend, indemnify,
and hold harmless the Indemnitees from and against any and all loss, liability,
expense, or damage (including investigative costs, court costs and attorneys’
fees) Indemnitees may suffer, pay, or incur as a result of claims, demands or
actions brought by a third party against any of the Indemnitees arising or
alleged to arise by reason of or in connection with

 

12

 

[*] caused or contributed to in whole or in part by
LICENSEE’s [*], except, in each case, to the
extent such claims, demands or actions result from the [*] of
any Indemnitee or the [*] in this
Agreement. LICENSEE’s obligations under this Article shall survive the
expiration or termination of this Agreement for any reason.

 

11.3         Insurance. Without limiting LICENSEE’s indemnity
obligations under the preceding paragraph, LICENSEE shall maintain throughout
the term of this Agreement and for ten (10) years thereafter a liability
insurance policy which:

 

(a)           insures Indemnitees for all claims, damages, and actions
mentioned in Article 10.1 of this Agreement;

 

(b)           includes a contractual endorsement providing coverage for
all liability which may be incurred by Indemnitees in connection with this
Agreement;

 

(c)           requires the insurance carrier to provide MCGRI with no
less than thirty (30) days written notice of any change in the terms or
coverage of the policy or its cancellation; and

 

(d)           prior to the initiation of the first clinical trial
involving a Licensed Product, provides product liability coverage in an amount
no less than two million dollars ($2,000,000) per occurrence for bodily injury
and one million dollars ($1,000,000) per occurrence for property damage,
subject to a reasonable aggregate amount.

 

11.4         Notice of Claims. LICENSEE shall promptly notify
MCGRI of all claims involving the Indemnitees and will advise MCGRI of the
policy amounts that might be needed to defend and pay any such claims.

 

ARTICLE 12.  TERM AND TERMINATION

 

12.1         Term. Unless sooner terminated as otherwise provided
in this Agreement, the term of this Agreement shall commence on the date hereof
and shall continue until the date of expiration of the last to expire of the
Licensed Patents, including any renewals or extensions thereof.

 

12.2         Termination. MCGRI shall have the right to terminate
this Agreement upon the occurrence of any one or more of the following events:

 

(a)           failure of LICENSEE to make any two payments consecutive
required pursuant to this Agreement when due; or

 

(b)           failure of LICENSEE to render reports to MCGRI as required
by this Agreement; or

 

13

 

(c)           failure of LICENSEE to notify MCGRI of intent to file
bankruptcy as set forth in Article 12.3 below;

 

(d)           the insolvency of LICENSEE; or

 

(e)           the institution of any proceeding by LICENSEE under any
bankruptcy, insolvency, or moratorium law; or

 

(f)            any assignment by LICENSEE of substantially all of its
assets for the benefit of creditors; or

 

(g)           placement of LICENSEE’s assets in the hands of a trustee
or a receiver unless the receivership or trust is dissolved within thirty (30)
days thereafter; or

 

(h)           the breach of any other material term of this Agreement.

 

12.3         Notice of Bankruptcy. The LICENSEE must inform MCGRI
of its intention to file a voluntary petition in bankruptcy or of another’s
intention to file an involuntary petition in bankruptcy to be received at least
thirty (30) days prior to filing such a petition. A party’s filing without
conforming to this requirement shall be deemed a material, pre-petition
incurable breach.

 

12.4         Exercise. MCGRI may exercise its right of termination
by giving LICENSEE, its trustees or receivers or assigns, thirty (30) days
prior written notice of MCGRI’s election to terminate. Upon the expiration of
such period, this Agreement shall automatically terminate unless the LICENSEE
has cured the breach. Such notice and termination shall not prejudice MCGRI’s
right to receive royalties or other sums due hereunder and shall not prejudice
any cause of action of claim of MCGRI accrued or to accrue on account of any
breach or default by LICENSEE.

 

12.5         Failure to Enforce. The failure of MCGRI at any time,
or for any period of time, to enforce any of the provisions of this Agreement
shall not be construed as a waiver of such provisions or as a waiver of the
right of MCGRI thereafter to enforce each and every such provision.

 

12.6         Termination by LICENSEE.  LICENSEE shall have the right to terminate
this Agreement upon the occurrence the breach of a material term of this
Agreement by MCGRI. In addition, LICENSEE may, upon sixty (60) days written
notice to MCGRI, terminate this Agreement by doing all of the following:
ceasing to make, have made, use, import, sell and offer for sale all Licensed
Products; returning any confidential materials provided to Licensee by MCGRI in
connection with this Agreement; paying all amounts owed to MCGRI under this
Agreement, up to the date of termination.

 

12.7         Exercise. LICENSEE may exercise its right of
termination based upon a material breach of this Agreement by MCGRI by giving
MCGRI thirty (30) days prior written notice of LICENSEE’s election to
terminate. Upon the expiration of such period, this Agreement shall
automatically terminate unless MCGRI has cured the breach. Such notice and
termination shall not prejudice LICENSEE’s right to pursue any other remedies
available to LICENSEE at law.

 

14

 

12.8         Effect. In the event this Agreement is terminated for
any reason whatsoever, LICENSEE shall return, or at MCGRI’s direction destroy,
all plans, drawings, papers, notes, writings and other documents, samples,
organisms, biological materials and models pertaining to the Licensed Patents
and Licensed Technology, retaining no copies, and shall refrain from using or
publishing any portion of the Licensed Patents or Licensed Technology as
provided in Article 8 of this Agreement. Upon termination of this
Agreement, LICENSEE shall cease manufacturing, processing, producing, using,
Selling, or distributing Licensed Products; provided, however, that LICENSEE
may continue to Sell in the ordinary course of business for a period of one (1) year
reasonable quantities of Licensed Products which are fully manufactured and in
LICENSEE’s normal inventory at the date of termination if (a) all monetary
obligations of LICENSEE to MCGRI have been satisfied and (b) royalties on
such sales are paid to MCGRI in the amounts and in the manner’ provided in this
Agreement. The provisions of Articles 9, 10, and 11 of this Agreement shall
remain in full force and effect notwithstanding the termination of this
Agreement.

 

ARTICLE 13.  ASSIGNMENT

 

This
Agreement is dependent upon the special relationship between the parties and
the special knowledge and unique skills of the LICENSEE. Therefore, LICENSEE
shall not grant, transfer, convey, or otherwise assign any of its rights or
delegate any of its obligations under this Agreement without the prior written
consent of MCGRI, except that Licensee may assign this Agreement without the
prior written consent of MCGRI, to any Affiliate, or in connection with the
transfer or sale of all or substantially all of Licensee’s business to which
this Agreement relates to a third party, whether by merger, sale of stock, sale
of assets or otherwise. This Agreement shall be assignable by MCGRI to MCG, or
any other nonprofit corporation which promotes the education or research
purposes of MCG.

 

ARTICLE 14.  MISCELLANEOUS

 

14.1         Export Controls. LICENSEE acknowledges that MCGRI is
subject to United States laws and regulations controlling the export of
technical data, computer software, laboratory prototypes, and other commodities
and that MCGRI’s obligations under this Agreement are contingent upon
compliance with applicable United States export laws and regulations. The
transfer of technical data and commodities may require a license from the
cognizant agency of the United States government or written assurances by
LICENSEE that LICENSEE shall not export data or commodities to certain foreign
countries without the prior approval of certain United States agencies. MCGRI
neither represents that an export license shall not be required nor that, if
required, such export license shall issue.

 

14.2         Legal Compliance. LICENSEE shall comply with all laws
and regulations applicable to its manufacture, processing, producing, use,
Selling, or distributing of Licensed Products.

 

15

 

14.3         Independent Contractor. LICENSEE’s relationship to
MCGRI shall be that of a licensee only. LICENSEE shall not be the agent of
MCGRI and shall have no authority to act for or on behalf of MCGRI in any
matter. Persons retained by LICENSEE as employees or agents shall not by reason
thereof be deemed to be employees or agents of MCGRI.

 

14.4         Patent Marking. LICENSEE shall mark Licensed Products
Sold in the United States with United States patent numbers. Licensed Products
manufactured or Sold in other countries shall be marked in compliance with the
intellectual property laws in force in such foreign countries.

 

14.5         Use of Names. LICENSEE shall obtain the prior written
approval of MCGRI, MCG, or the Inventors prior to making use of their names for
any commercial purpose.

 

14.6         Place of Execution. This Agreement and any subsequent
modifications or amendments hereto shall be deemed to have been executed in the
State of Georgia, U.S.A. This Agreement shall not become effective or binding
upon MCGRI until signed on its behalf by its Executive Director in the State of
Georgia, U.S.A.

 

14.7         Governing Law. This Agreement and all amendments,
modifications, alterations, or supplements hereto, and the rights of the
parties hereunder, shall be construed under and governed by the laws of the
State of Georgia and the United States of America. Only courts in the State of
Georgia, U.S.A., shall have jurisdiction to hear and decide any controversy or
claim between the parties arising under or relating to this Agreement.

 

14.8         Entire Agreement. This Agreement constitutes the
entire agreement between MCGRI and LICENSEE with respect to the subject matter
hereof and shall not be modified, amended or terminated except as herein
provided or except by another agreement in writing executed by the parties
hereto.

 

14.9         Severability. All rights and restrictions contained
herein may be exercised and shall be applicable and binding only to the extent
that they do not violate any applicable laws and are intended to be limited to
the extent necessary so that they will not render this Agreement illegal,
invalid or unenforceable. If any provision or portion of any provision of this
Agreement not essential to the commercial purpose of this Agreement shall be
held to be illegal, invalid or unenforceable by a court of competent
jurisdiction, it is the intention of the parties that the remaining provisions
or portions thereof shall constitute their agreement with respect to the
subject matter hereof, and all such remaining provisions or portions thereof
shall remain in full force and effect. To the extent legally permissible, any
illegal, invalid or unenforceable provision of this Agreement shall be replaced
by a valid provision which will implement the commercial purpose of the
illegal, invalid or unenforceable provision. In the event that any provision
essential to the commercial purpose of this Agreement is held to be illegal,
invalid or

 

16

 

unenforceable
and cannot be replaced by a valid provision which will implement the commercial
purpose of this Agreement, this Agreement and the rights granted herein shall
terminate.

 

14.10       Force Majeure. Any delays in, or failure of,
performance of any party to this Agreement shall not constitute default
hereunder, or give rise to any claim for damages, if and to the extent caused
by occurrences beyond the control of the party affected, including, but not
limited to, acts of God, strikes or other work stoppages; civil disturbances,
fires, floods, explosions, riots, war, rebellion, sabotage, acts of
governmental authority or failure of governmental authority to issue licenses
or approvals which may be required.

 

ARTICLE 15.  NOTICES

 

All
notices, statements, and reports required or contemplated herein by one party
to the other shall be in writing and shall be deemed to have been given upon
delivery in person or upon the expiration of five (5) days after deposit
in a lawful mail depository in the country of residence of the party giving the
notice, registered or certified airmail postage prepaid, and addressed as
follows:

 

	
  If
  to MCGRI:

  	
   

  
	
   

  	
   

  
	
   

  	
  Associate
  Vice President

  
	
   

  	
  Office
  of Technology Transfer & Economic Development

  
	
   

  	
  Medical
  College of Georgia Research Institute, Inc.

  
	
   

  	
  CA-2125

  
	
   

  	
  Medical
  College of Georgia

  
	
   

  	
  Augusta,
  Georgia 30912-9824

  
	
   

  	
  Facsimile:
  (706) 721-2917

  
	
   

  	
   

  
	
  With
  a copy to:

  	
  Legal
  Advisor

  
	
   

  	
  Medical
  College of Georgia Research Institute, Inc.

  
	
   

  	
  CJ-3301

  
	
   

  	
  Medical
  College of Georgia

  
	
   

  	
  Augusta,
  Georgia 30912-4810

  
	
   

  	
  Facsimile:
  (706) 721-7603

  
	
   

  	
   

  
	
  If
  to LICENSEE:

  	
  NewLink
  Genetics Corporation

  
	
   

  	
  Chief
  Medical Officer

  
	
   

  	
  2901
  South Loop Dr, Suite 3900

  

 

17

 

	
   

  	
  Ames, IA
  50010 

  
	
   

  	
  Facsimile:
  (515) 296-5557

  

 

Either
party hereto may change the address to which notices to such party are to be
sent by giving notice to the other party at the address and in the manner
provided above. Any notice herein required or permitted to be given may be
given, in addition to the manner set forth above, by telex, facsimile or cable,
provided that the party giving such notice obtains acknowledgement by telex,
facsimile or cable that such notice has been received by the party to be
notified. Notice made in this manner shall be deemed to have been given when
such acknowledgement has been transmitted.

 

IN
WITNESS WHEREOF, MCGRI and LICENSEE have caused this Agreement to be signed by
their duly authorized representatives as of the day and year indicated below.

 

 

	
  MEDICAL
  COLLEGE OF GEORGIA

  	
   

  	
  LICENSEE:

  
	
  RESEARCH
  INSTITUTE, INC.

  	
   

  	
  NEWLINK
  GENETICS CORPORATION

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/
  Betty Aldridge

  	
   

  	
  By:

  	
  /s/
  Nicholas Vahanian

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Name:

  	
  Betty
  Aldridge

  	
   

  	
  Name:

  	
  Nicholas
  Vahanian

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  Executive
  Director

  	
   

  	
  Title:

  	
  Chief
  Medical and Operations Officer

  

 

18

 

EXHIBIT A

 

LICENSED PATENTS

 

[*]

 

19

 

EXHIBIT B

 

STOCK SUBSCRIPTION AGREEMENT

 

20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}]]